• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    CooperCompanies Appoints Paul Keel to its Board of Directors

    5/4/26 4:15:00 PM ET
    $COO
    $NVST
    Ophthalmic Goods
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $COO alert in real time by email

    SAN RAMON, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, announced today that its Board of Directors has appointed Paul Keel as an independent director, effective July 1, 2026. Mr. Keel has also been appointed to serve on the Audit Committee when he joins the Board.

    "We are delighted to welcome Paul to our Board as a new Director," said Colleen Jay, Chair of the Board of CooperCompanies. "His experience as a CEO in the medical device sector, along with a successful track record of leading complex global operations, will be a significant asset as Cooper continues to execute its strategy and create long-term value for patients, customers, and shareholders."

    Mr. Keel has served as President and Chief Executive Officer of Envista Holdings Corporation (NYSE:NVST), a global specialty medical technology company, since 2024. Prior to joining Envista, Mr. Keel served as CEO of Smiths Group plc (LON: SMIN), a diversified global industrial technology company and FTSE constituent, from 2021 to 2024. Earlier, he spent 16 years at 3M, serving in various leadership roles, including Group President of 3M Consumer Business, President of 3M Medical, President of 3M Unitek, SVP of Manufacturing & Supply Chain, and SVP of Marketing, Sales & Business Development. Mr. Keel's career also includes roles at General Mills, General Electric, Norwest Equity Partners, and McKinsey & Company. He holds an MBA from Harvard Business School and a BA in Economics from Carleton College.

    About CooperCompanies

    CooperCompanies (NASDAQ:COO) is a leading global medical device company focused on helping people experience life's beautiful moments through its two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, helping to improve the way people see each day. CooperSurgical is a leading fertility and women's healthcare company dedicated to putting time on the side of women, babies, and families at the healthcare moments that matter most. Headquartered in San Ramon, CA, CooperCompanies has a workforce of more than 15,000, sells products in over 130 countries, and positively impacts over fifty million lives each year. For more information, please visit www.coopercos.com.

    Forward-Looking Statements

    This press release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Statements relating to the Company's efforts to enhance long-term shareholder value, plans, strategies, future actions, and other statements of which are other than statements of historical fact, are forward-looking. Forward-looking statements necessarily depend on assumptions, data, or methods that may be incorrect or imprecise and are subject to risks and uncertainties. Statements regarding future events and performance and contain words such as "expects" and similar words or phrases. A wide range of factors could materially affect future developments, including, but not limited to, uncertainties related to market conditions and other factors set forth in our other filings with the United States Securities and Exchange Commission, including our most recent Annual Report on Form 10-K. These risks and uncertainties may cause actual future results or actions to be materially different than those expressed in such forward-looking statements. We do not intend, or undertake any duty, to update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

    Contact:

    Kim Duncan

    Vice President, Investor Relations and Risk Management

    925-460-3663

    ir@cooperco.com



    Primary Logo

    Get the next $COO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $COO
    $NVST

    CompanyDatePrice TargetRatingAnalyst
    Envista Holdings Corporation
    $NVST
    4/15/2026$29.00Neutral
    Citigroup
    The Cooper Companies Inc.
    $COO
    3/4/2026$85.00Buy → Neutral
    Rothschild & Co Redburn
    Envista Holdings Corporation
    $NVST
    2/6/2026$35.00Market Perform → Outperform
    Leerink Partners
    The Cooper Companies Inc.
    $COO
    2/3/2026$100.00 → $99.00Buy
    Needham
    Envista Holdings Corporation
    $NVST
    12/9/2025$24.00Overweight
    Barclays
    The Cooper Companies Inc.
    $COO
    11/13/2025$72.00Overweight → Equal Weight
    Wells Fargo
    The Cooper Companies Inc.
    $COO
    10/13/2025$85.00Overweight
    Barclays
    The Cooper Companies Inc.
    $COO
    10/1/2025$64.00Sell
    Goldman
    More analyst ratings

    $COO
    $NVST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup initiated coverage on Envista with a new price target

    Citigroup initiated coverage of Envista with a rating of Neutral and set a new price target of $29.00

    4/15/26 8:08:24 AM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    Cooper downgraded by Rothschild & Co Redburn with a new price target

    Rothschild & Co Redburn downgraded Cooper from Buy to Neutral and set a new price target of $85.00

    3/4/26 8:35:56 AM ET
    $COO
    Ophthalmic Goods
    Health Care

    Envista upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded Envista from Market Perform to Outperform and set a new price target of $35.00

    2/6/26 8:05:48 AM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    $COO
    $NVST
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Keel Paul A covered exercise/tax liability with 12,811 shares, decreasing direct ownership by 3% to 371,574 units (SEC Form 4) to satisfy tax liability

    4 - Envista Holdings Corp (0001757073) (Issuer)

    5/27/26 4:17:15 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    Director Tsingos Christine A was granted 9,330 shares, increasing direct ownership by 18% to 59,930 units (SEC Form 4)

    4 - Envista Holdings Corp (0001757073) (Issuer)

    5/21/26 4:37:24 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    Director Carruthers Wendy was granted 9,330 shares, increasing direct ownership by 18% to 59,940 units (SEC Form 4)

    4 - Envista Holdings Corp (0001757073) (Issuer)

    5/21/26 4:37:30 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    $COO
    $NVST
    SEC Filings

    View All

    SEC Form 8-K filed by The Cooper Companies Inc.

    8-K - COOPER COMPANIES, INC. (0000711404) (Filer)

    6/4/26 4:27:28 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    Envista Holdings Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Envista Holdings Corp (0001757073) (Filer)

    6/3/26 4:54:52 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    SEC Form SD filed by The Cooper Companies Inc.

    SD - COOPER COMPANIES, INC. (0000711404) (Filer)

    5/29/26 4:26:32 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    $COO
    $NVST
    Leadership Updates

    Live Leadership Updates

    View All

    CooperCompanies Appoints Paul Keel to its Board of Directors

    SAN RAMON, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, announced today that its Board of Directors has appointed Paul Keel as an independent director, effective July 1, 2026. Mr. Keel has also been appointed to serve on the Audit Committee when he joins the Board. "We are delighted to welcome Paul to our Board as a new Director," said Colleen Jay, Chair of the Board of CooperCompanies. "His experience as a CEO in the medical device sector, along with a successful track record of leading complex global operations, will be a significant asset as Cooper continues to execute its strategy and create long-term value for patient

    5/4/26 4:15:00 PM ET
    $COO
    $NVST
    Ophthalmic Goods
    Health Care
    Medical/Dental Instruments

    CooperCompanies Appoints Walter M Rosebrough, Jr. to its Board of Directors

    SAN RAMON, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading medical device company, announced today that the Company's Board of Directors (the "Board") has appointed Walter (Walt) M Rosebrough, Jr. as an independent director, effective as of January 3, 2026. In connection with this appointment, the Company also has entered into a cooperation agreement (the "Cooperation Agreement") with Browning West, LP. ("Browning West"). Mr. Rosebrough will join the Board's Corporate Governance & Nominating Committee. The Board has also agreed that, by the end of 2026, it shall provide due and serious consideration for Mr. Rosebrough to be appointed Chair of the Board. In

    12/23/25 8:00:00 AM ET
    $COO
    $STE
    $VREX
    Ophthalmic Goods
    Health Care
    Industrial Specialties
    Industrial Machinery/Components

    Browning West Delivers Letter to The Cooper Companies Board of Directors

    Cooper's Lack of Strategic Focus, Misaligned Incentives, and Inadequate Board Oversight Have Led to Meaningful Underperformance Current Corporate Structure Obscures Value of Both CooperVision and CooperSurgical; Refocus as a Pure Play Vision Care Company Under a Refreshed Board May Lead to More Than a Doubling of Cooper's Stock Price Urges Cooper's Board to Appoint Browning West's Highly Skilled Director Candidates Who Will Improve the Company's Operating Plans Including Capital Allocation, Overhaul Management Incentives, and Evaluate Strategic Alternatives for CooperSurgical LOS ANGELES, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Browning West, LP ("Browning West", "us", or "we"), an investment

    11/19/25 8:45:00 AM ET
    $COO
    Ophthalmic Goods
    Health Care

    $COO
    $NVST
    Financials

    Live finance-specific insights

    View All

    CooperCompanies Announces Second Quarter 2026 Results

    SAN RAMON, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, today announced financial results for its fiscal second quarter ended April 30, 2026. Second quarter 2026 revenue of $1.082 billion, up 8%, or up 5% organically, from last year's second quarter.Second quarter 2026 GAAP diluted earnings per share (EPS) of $(0.40), down $0.84 from last year's second quarter driven by a litigation-related charge to resolve outstanding claims associated with a December 2023 voluntary product recall at CooperSurgical.Second quarter 2026 Non-GAAP diluted EPS of $1.21, up $0.25 or 26% from last year's second quarter. See "Reconciliation of

    6/4/26 4:15:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    CooperCompanies Announces Release Date for Second Quarter 2026

    SAN RAMON, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, announced today it will report second quarter 2026 financial results on Thursday, June 4, 2026, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 6529381. A simultaneous audio webcast and subsequent replay can be accessed at www.investor.coopercos.com About CooperCompanies CooperCompanies (NASDAQ:COO) is a leading global medical device company focused on helping people experience life's beauti

    4/30/26 4:15:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    Envista Schedules First Quarter 2026 Earnings Call

    BREA, Calif., April 8, 2026 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) ("Envista") will report financial results for its first quarter 2026 on Wednesday, May 6, 2026. Envista will discuss these results on a conference call on the same day beginning at 2:00 PM PT and lasting approximately one hour.  The call and the accompanying slide presentation will be webcast on the "Investors" section of Envista's website, www.envistaco.com. A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available for one year. You can

    4/8/26 4:10:00 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    $COO
    $NVST
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CooperCompanies Announces Second Quarter 2026 Results

    SAN RAMON, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, today announced financial results for its fiscal second quarter ended April 30, 2026. Second quarter 2026 revenue of $1.082 billion, up 8%, or up 5% organically, from last year's second quarter.Second quarter 2026 GAAP diluted earnings per share (EPS) of $(0.40), down $0.84 from last year's second quarter driven by a litigation-related charge to resolve outstanding claims associated with a December 2023 voluntary product recall at CooperSurgical.Second quarter 2026 Non-GAAP diluted EPS of $1.21, up $0.25 or 26% from last year's second quarter. See "Reconciliation of

    6/4/26 4:15:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    CooperVision Names Muru Annamalai as President, Asia-Pacific

    Experienced Global Healthcare Leader to Guide Growth Across the RegionSINGAPORE, May 29, 2026 /PRNewswire/ -- CooperVision has named Muru Annamalai as President, Asia-Pacific, effective June 1, 2026. He brings more than two decades of global leadership experience across the pharmaceutical and healthcare sectors, with extensive expertise leading commercial organizations and driving growth across Asia-Pacific, Latin America, and other global markets. His appointment reflects CooperVision's broader investment in guiding the company's next phase of growth across one of its most dynamic and strategically important regions.

    5/29/26 8:05:00 AM ET
    $COO
    Ophthalmic Goods
    Health Care

    Henry Schein Announces the Election of William K. "Dan" Daniel as Independent Chairman of the Board

    Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today announced that its Board of Directors has elected William K. "Dan" Daniel as Independent Chairman of the Board, effective May 21, 2026. Mr. Daniel succeeds Stanley M. Bergman, who retired from the Board following 44 years as a Director of Henry Schein and was named Chairman Emeritus in recognition of his extraordinary contributions to the Company. Mr. Daniel joined the Henry Schein Board of Directors in May 2025. He possesses decades of board and global executive leadership experience in healthcare and industrial sectors, including serving for 14

    5/22/26 8:00:00 AM ET
    $DHR
    $HSIC
    $NVST
    Industrial Machinery/Components
    Industrials
    Medical Specialities
    Health Care

    $COO
    $NVST
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lucchese Cynthia L bought $149,963 worth of shares (1,784 units at $84.06), increasing direct ownership by 23% to 9,445 units (SEC Form 4)

    4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

    12/23/25 4:08:36 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    Director Rivas Maria bought $82,130 worth of shares (1,000 units at $82.13) (SEC Form 4)

    4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

    12/19/25 4:18:51 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    Director Kurzius Lawrence Erik bought $165,000 worth of shares (2,000 units at $82.50), increasing direct ownership by 35% to 7,777 units (SEC Form 4)

    4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

    12/17/25 5:06:19 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    $COO
    $NVST
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Envista Holdings Corporation

    SC 13G - Envista Holdings Corp (0001757073) (Subject)

    11/8/24 12:09:03 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by The Cooper Companies Inc. (Amendment)

    SC 13G/A - COOPER COMPANIES, INC. (0000711404) (Subject)

    2/16/24 4:57:01 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    SEC Form SC 13G/A filed by Envista Holdings Corporation (Amendment)

    SC 13G/A - Envista Holdings Corp (0001757073) (Subject)

    2/15/24 10:19:33 AM ET
    $NVST
    Medical/Dental Instruments
    Health Care